anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
NEW MATERIAL:A compound shown by formula I (R&lt;1&gt; is H or lower alkoxy; A is O, S, N, CH=N, etc.) and a salt thereof. EXAMPLE:2-(4,5,6,7-Tetrahydro-5-benzimidazolyl)-3,4-dihydroquinazoline. USE:An antiemetic drug suppressing vomiting caused by carcinostatic agent such as cisplatin and by radiation. PREPARATION:According to the reaction formula, an aniline derivative shown by formula II is reacted with 4,5,6,7-tetrahydrobenzimidazole-5-carboxylic acid shown by formula III or a reactive derivative thereof to given compound shown by formula I. The reaction is usually carried out in a solvent (e.g. acetone, dioxane or ether) at room temperature or under heating.
PURPOSE:To obtain a prepack agent, used before a film-forming pack and having sufficient deterging effects without any pain in peeling by blending a skin softener with a water-soluble polymer. CONSTITUTION:The objective substance obtained by blending &gt;=10wt.% skin softener (e.g. ethylene glycol or glycerol) with 0.01-5wt.% water-soluble polymer (e.g. polyacrylic acid or carboxyvinyl polymer), as necessary, suitably blending a normally used oily ingredient, humectant, thickener, surfactant, antioxidant, ultraviolet ray absorber, drug effect ingredient, perfume, etc., therewith and preparing a prepack. The resultant prepack is applied to the face, allowed to the stand for a while and then wiped off. A film-forming type pack is then applied thereon to provide moist skin without any pain even by peeling the film-forming type pack.
Peptides of formula (I): R-CH-CO-Gly-Asn-Leu-Ser-Thr-Cys-X-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Phe- -Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-- NH2 (I) (where R is H or free or acylated amino; X is a valine norvaline, leucine, isoleucine, morleucine or alpha-aminobutyric acid residue) and the corresp. cpds. in which &gt;=1 of the Asn or Gln residues are replaced by Asp and Glu respectively and/or the Asp residue is replaced by Asn. and their acid-addn. salts and Zn complexes, are new and can be prepd. by standard methods from the appropriate protected amino acids, the disulphide bridge being formed by oxidn. and the terminal COOH gp. being amidated.
PROBLEM TO BE SOLVED: To obtain a hair tonic and a hair cosmetic, capable of promoting regeneration of hair and the growth of the hair in spare hair or alopecia by activating hair follicle by including an extract of the mycelium of Agaricus blazei Murill. SOLUTION: The hair tonic and hair cosmetic contain an extract of the mycelium of Agaricus blazei Murill and/or a filtrate of a liquid culturing the mycelium of the Agaricus blazei Murill. The Agaricus blazei Murill is a species belonging to the genus Agaricus of the family Agaricaceae of the order Agaricales in the kind Basidiomycetes, and also called &#39;Kawariharatake&#39; and &#39;Himematsutake&#39;. The Agaricus blazei Murill is spread out in the southeast part of North America, and South America, and is the one of mushroom used to be eaten by the inhabitant in the southeast part of Brazil. The Agaricus blazei Murill is deposited in Fermentation Research Institute, Agency of Industrial Science and Technology, as an accession no. FERM 4731. The culturing method of the Agaricus blazei Murill is preferably a liquid culturing method.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an external preparation for skins, excellent in a moisture-retaining property and the like, although various cosmetics containing the extracts of plants, such as a cosmetic containing an extract of morning-glory, a cosmetic containing the extract of strawberry, and a cosmetic containing an extract of carnation are known.  &lt;P&gt;SOLUTION: Provided is the external preparation for the skins, containing an extract of a plant belonging to Leucojum or Disporum, such as Leucojum autumnale L., Leucojum aestivum L., Disporum viridescens (Maxim) Nakai, Disporum lutescens (Maxim) Koidz., Disporum smilacinum A. Gray, Disporum sessile Don var. micranthum Hatus., or Disporum sessile Don. The external preparation is excellent in a moisture-retaining property and the like, and is useful as a cosmetic and the like.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new gene expression promoting agent for skin beautifying use, effective for promoting the expression of a skin-beautifying gene such as aquaporin 3, aquaporin 5, serine palmitoyl transferase enzyme and hyaluronic acid synthase.  &lt;P&gt;SOLUTION: The gene expression promoting agent for skin beautifying use contains an extract of a plant of the genus Fragaria L., family Rosaceae as an active component. The extract preferably contains tiliroside. The part of the plant of the genus Fragaria L., family Rosaceae to be used in the agent is preferably seed. The invention is widely usable for foods, drinks, pharmaceuticals, skin care preparations, etc.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE: To produce a nonalcoholic solid get in the form of a transparent pan or a stick having hydrating properties for skin by combining and using a dibenzylidene-ose with a sulfosuccinate type hardening agent as a gelling agent. CONSTITUTION: This nonalcoholic solid cosmetic get is in the form of a pan or a stick as a new industrial product. The gel comprises 65-99 wt.% polyol, 0.1-5 wt.% dibenzylidene-ose, 0.1-5 wt.% sulfosuccininate type hardening agent and 0.5-40 wt.% water. The hardened nonalcoholic gel is formed by synergistic actions of the dibenzylidene-ose and the sulfosuccinate type hardening agent by using both in combination. A compound represented by formula [X and X&#39; are each H, a halogen, a 1-4C alkyl, a 1-4C alkoxy or carboxy; (m) and (n) are each 0-5; (p) is 0 or 1] is preferred as the dibenzylidene-ose and a compound represented by formula II [R is a bivalent group; (x) and (y) are each a number so as to provide 700-1,600 molecular weight; M is Na, etc.] is preferred as the sulfosuccininate type hardening agent.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a detergent for hair having even excellent sebum removing effects.  &lt;P&gt;SOLUTION: The detergent for hair comprises an anionic surfactant, an amphoteric surfactant and an amide condensate, or the like, of a fatty acid with a hydroxy(1-4C) alkylamine. 1,2-Pentanediol and 1,2-hexanediol are included in the detergent. The sum total of the contents of the 1,2-pentanediol and 1,2-hexanediol is preferably 0.1-5 wt.%, more preferably 0.5-3 wt.% based on the total amount of the subject cosmetic. The cosmetic comprises a polymer having a single amino acid residue and/or its salt in a preferred form as a preferable ingredient.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
A triple natural polymer viscoelastic composition is disclosed. By combining glucosamine sulfate (&#34;GS&#34;), sodium hyaluronate (&#34;HA&#34;) and chondroitin sulfate (&#34;CS&#34;), the triple natural polymer viscoelastic compositions of this invention can provide a viscoelastic agent at a surgical site that not only serves as a protective agent to ocular tissues, but that can also act as an agent to alleviate pain and inflammation associated with ocular surgery. Embodiments of this invention can comprise GS combined with existing HA/CS viscoelastic agents. Embodiments of this invention can also comprise GS and CS in combination with an irrigation solution. Further, to enhance retention time at the site of an intra-articulate application of an embodiment of this invention, the following biodegradable polymers may also be included in an embodiment of the compositions of the present invention: cellulose derivatives (e.g., hydroxypropylmethylcellulose, ethylcellulose, caboxymethylcellulose, etc.), carbopol , citosan, and collagen.
PURPOSE:To obtain spherical anhydrous calcium secondary phosphate capable of polishing and cleaning teeth without damaging the surfaces of the teeth when used as a polishing agent for toothpaste by prescribing the average roundness of spherical anhydrous calcium secondary phosphate, the rate of liq. absorption, the angle of repose, the specific surface area and the average particle size. CONSTITUTION:A Ca compound such as CaO is reacted with a phosphoric acid compound such as phosphoric acid at &gt;=50 deg.C in the presence of a condensation product of phosphoric acid such as tripolyphosphoric acid. At this time, it is necessary to use the phosphoric acid compound by &gt;=10pts.wt. per 100pts.wt. CaO when the Ca compound is expressed in terms of CaO. Spherical anhydrous calcium secondary phosphate obtd. by said reaction has 0.6-1.0 average roundness, 0.4-0.7ml/g rate of liq. absorption, 10-50 deg. angle of repose, 1-100m&lt;2&gt;/g specific surface area and 1-100mum average particle size. This phosphate is entirely different from conventional common anhydrous calcium secondary phosphate in physical properties as well as shape. The conventional phosphate has 0-0.4 average roundness, 0.2-0.4ml/g rate of liq. absorption and 50-60 deg. angle of repose.
Patients are evaluated in terms of various physiological parameters such as hemodynamic parameters. Covariate information indicative of the patient&#39;s individual characteristics may also be determined. A state variable indicative of the patient&#39;s characteristics is determined. This state variable is used to compare the patient to other patients in the database. The other patients in the database are evaluated in terms of similar parameters and their probability of survival as well as different treatments and the probability of survival based on those different treatments. The patient may be simply evaluated based on the database or a proper course of treatments may be determined based on the database.
283,265. Kawai, K. Oct. 5, 1926. Medicines for internal use. - A concentrate of cod-liver oil rich in vitamin A is prepared by saponifying 50-75 per cent of the saponifiable portion of ordinary cod-liver oil and then separating the unsaponified oil, containing vitamin A and other effective ingredients, from the saponified matter. The oil may be saponified by adding caustic soda and stirring for about 2 hours at a temperature below 60‹ C. Separation of the saponified and unsaponified matters may be effected by allowing the mass to stand, when the saponified matter sinks to the bottom; the oil at the top is removed, saponified matter remaining therein is extracted bv washing &amp;c., and the oil is then further refined in a centrifugal separating apparatus. Or milk of lime may be added and the mass heated slightly, steam being introduced to prevent oxidation, and, after cooling, the calcium soap is separated from the mass by a filter press or a centrifugal apparatus and then by allowing the mass to stand etc.; or milk of lime and alcohol may be added to the cod-liver oil to effect the saponification.
The present invention relates to the field of medical technology, and in particular relates to a category of novel sulphonyl substituted xanthene ketone compounds that have a structural formula shown as follows, a preparation method and application thereof. The compound has high inhibitory activity for ACAT1/ACAT2; most of the compounds have high inhibitory activity for acyl coenzyme A cholesterol acyltransferase (ACAT). The compounds can be used for preparing anti-atherosclerosis drug combination. Furthermore, the compounds can be used as a preventive or a treating agent of such diseases as angina, myocardial infarction, cerebral infarction, apoplexy, Alzheimer&#39;s disease, acute coronary syndrome, PTCA or restenosis of coronary artery after a bracket is arranged. The compounds can be used as a treating agent to adjust the function of sebaceous glands of the skin and inhibit the excessive generation of sebum. And the compounds can be used for treating such diseases as acne-like damage caused by oily skin, acne, seborrhea and corticosteroids.
PURPOSE:To provide a new N-alkyl-thiazolidine derivative useful as a theraperctic agent for hepatic diseases such as acute hepatic insufficiency, chronic hepatitis, acute hepatitis or liver cirrhosis. CONSTITUTION:Compounds represented by formula I (X is O or S; R&lt;1&gt; is lower alkyl which may be substituted with OH, COOH or lower alkoxycarbonyl; R&lt;2&gt; is H, lower alkanoyl, phenyl-lower alkanoyl or phenyl-lower alkyl phenyl ring of which may be substituted with lower alkyl or lower alkoxy; A is 1-6C straight or branched chain alkylene) and salts thereof, e.g. (4R)-3-[2-(4- methoxybenzylthio)-2-methylpropyl]-4-methoxycarbonylthiazolidine-2-thi one. These compounds can be obtained by reacting a compound of formula II with a compound of formula III. In addition, the above-mentioned compounds are useful as the aforesaid medical drug and can be administrated by both the oral and parenteral administration. The dosage is 1-5000mg/day in general and daily administration can be carried out once or divided in several times.
Dendritic derivatives of 3,5-bis(aminomethyl)benzene and aminomethyl benzene core groups are disclosed. In each derivative, termed an &#34;amplifier&#34; because the dendritic structure on each molecule terminates with multiple termini to each of which an &#34;active group&#34; can be attached, the desired effect of the active group per mole is amplified compared to conventional compounds having only one active group per molecule. Amplifier molecules can include a targeting group permitting the molecules to preferentially attach to a particular anatomical or physiological situs. Active groups are any of various pharmacologically or therapeutically active moieties, including moieties useful for magnetic-resonance contrast enhancement. The dendritic structures comprise linkers and branch groups covalently bonded to each other in any of various structural combinations. The amplifiers can be prepared as a solution or mixture with a physiologically compatible carrier for administration to a warm-blooded animal subject. Also disclosed are methods for using the compounds in diagnosis and therapy, such as obtaining a magnetic resonance image of a subject.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for monitoring IL-18.  &lt;P&gt;SOLUTION: The present invention relates to the method suitable for monitoring IL-18. The present invention also provides a method for measuring IL-18 in a human body fluid for the purpose of diagnosing disease and evaluating the response to ICE inhibitor or other therapy. These methods are useful in discovering or developing compounds that modulate IL-18. Monitoring IL-18 levels provides a method for monitoring both IL-18-mediated and IL-1 β mediated disease processes.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a cosmetic excellent in compatibility with raw materials for usual cosmetics, capable of exhibiting an excellent emulsifying ability and further excellent cleaning effects and a good feeling of use by formulating a specific silicone compound. SOLUTION: This cosmetic is obtained by formulating a silicone compound represented by formula I [R1 is H, a 1-30C alkyl, an aryl, an aralkyl or the like; R2 is a group represented by formula II (f and g are each 1&lt;=f&lt;=5; 0&lt;=g&lt;=500); a and b are each 1.0&lt;=a&lt;=2.5; 0.001&lt;=b&lt;=1.5]. The silicone compound represented by formula I can readily be synthesized by carrying out an addition reaction of, e.g. an organohydrogenpolysiloxane with a silicone compound represented by formula III, as necessary, further an alkylene compound in the presence of a platinum or a rhodium catalyst. The silicone compound represented by formula I can be used as all the cosmetic raw materials externally used in skin or hair and is preferably formulated in an amount of 0.1-80 wt.% based on the whole cosmetic. An oil can further be contained in the cosmetic.
1,178,622. Making capsules. CHAS. PFIZER &amp; CO. Inc. 15 March, 1967 [23 Aug., 1966], No. 12260/67. Heading A5B. [Also in Divisions B5 and B8] Water-immiscible pharmaceutical materials are encapsulated by forming an aqueous dispersion thereof in a colloidal sol of a pharmaceutically acceptable hydrophilic polysaccharide or animal protein, centrifugally projecting minute portions of the dispersion completely through an unsupported film of warm, aqueous gelatin sol and cooling the resultant gelatin coated droplets. The apparatus described comprises a rotating head 10 on a vertical drive shaft 11 with a central feed device consisting of a tube 13 through which the gelatin sol is fed and a concentric inner tube 18 for the dispersion to be encapsulated. The gelatin sol passes under centrifugal force to the head containing an orifice 17 over which it forms a film and the dispersion passes to the nozzle 22 from which droplets are detached and pass through the gelatin film over the orifice 17. Thereafter, the coated droplets are cooled and collected. Specific reference is made to encapsulating fat-soluble vitamins, antibiotics, amphetamine, ephedrine, theophylline, hydroxyzine and oxyphencyclimine.
PROBLEM TO BE SOLVED: To obtain the subject new compound for inhibiting the proliferation of tumor cell and exhibiting carcinostatic effects. SOLUTION: A compound of formula I (R&lt;1&gt; is H or methyl; R&lt;2&gt; is O or imino) such as a compound of formula II. The compound of formula I is obtained inoculating a strain capable of producing BE-45985s in a nutrient source- containing medium and aerobically growing the strain to give a culture containing BE-45985s. Glucose, maltose, starch, etc., can be used as the nutrient source. Shaking culture and submerged aerated spinner culture are preferable as the culture method in the case of liquid culture. The culture temperature is 18-29 deg.C, the pH of the medium is 4-8 and the culture time is 96-360 hours. The separation and purification is carried out by filtering the culture solution and extracting the prepared cell with an organic solvent such as methanol or acetone.  The crude extract is subjected to water-ethyl acetate partition, ethyl acetate is distilled away and the extract is subjected to reversed phase column chromatography to give the, objective substance.
The invention discloses a pulse data classification method and device based on semi-supervised discrimination projection. The specific classification method comprises the following steps: 1. pressure pulse data is collected. 2. And (3) preprocessing and feature extraction are carried out on the data collected in the step (1). 3. And establishing a semi-supervised discrimination projection model, searching an optimal subspace by using a projection matrix, clustering in the space, labeling a label-free sample, and adding the next round of training to realize semi-supervised learning of pulse data. 4. And analyzing the projection matrix, and acquiring the contribution degree of each characteristic to the current task by solving the &#39;row normalization two-norm&#39; of the projection matrix. The pulse data classification device is used for realizing the classification steps. The invention provides a high-precision pulse data classification task tool through a judgment projection method, so that the feature importance is quantized, and a good experimental effect is obtained.
The invention belongs to the technical field of pharmaceutical chemistry, and particularly relates to a lysophosphatidic acid receptor antagonist and a preparation method thereof. The applicant has surprisingly found that the compounds of the present invention have high LPAR1 antagonistic activity and selectivity, low toxicity, good metabolic stability and good drug development prospects, and can be used for preventing or treating diseases or conditions related to LPAR 1. Applicants have also unexpectedly found that IC&#39;s of certain compounds of the present invention  50  Values can be as low as 300nM or less, even 50nM or less. Moreover, the compounds of the invention have better safety and CC  50  The range can be up to 200 mu M or more. Furthermore, the compounds of the present invention have good metabolic stability in humans, rats, mice, such excellent inhibitory activity being highly desirable for their application as LPAR1 inhibitors in the above diseases or conditions. In addition, the preparation method of the compound is simple, the reaction condition is mild, the product yield is high, and the compound is suitable for industrial production.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an enzyme having high ability to split melanins, and to provide a method for safely and efficiently splitting melanins using the enzyme.  &lt;P&gt;SOLUTION: The enzyme has the following characteristics: (1) A melanin derived from the hair is split with manganese as the essential component in the presence of hydrogen peroxide. (2) The optimum pH for the splitting reaction is 6 or lower. (3) The splitting activity(specific activity U/mg) for human hair at pH4.5 is two fold or greater that of a horseradish-derived peroxidase. The method for splitting melanins comprises making the enzyme act on the melanins in the presence of manganese and hydrogen peroxide. A gene encoding the enzyme is also provided.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
A method for synthesizing a medicinal, nutraceutical, or food fullerene composition, including providing anisotropy in polar and non-polar C60 fullerene hemispheres to create one face of C60 fullerene having a small number of OH-groups clustered to the polar face; providing an amount of a polyhydroxylated fullerene from C60 fullerene; and blending the amount of the polyhydroxylated fullerene with an acceptable ionomer or an acceptable carrier or both. The polyhydroxylated fullerene includes fullerol-&#39;x′ and the amount includes 200 ppm or 500 ppm, wherein ‘x’ is less than 22. The acceptable ionomer includes honey, or a mixture of 3% by wt. sucrose, 1% by wt. proline, 0.2% by wt. magnesium citrate, and 1% by wt. beta-cyclodextrin. The acceptable carrier includes water or a gelatin. A stent, a medical bandage, medical packing material, medical drainage material, acupuncture support, topical ointment, or suture material is impregnated with an anisotropic polyhydroxylated fullerene for antimicrobial action.
PURPOSE:To provide the dialysis pharmaceutical having excellent stability and water solubility by laminating a layer contg. org. acids and a layer contg. bicarbonate via an intermediate layer held therebetween, thereby preparing the laminated pharmaceutical contg. the electrolyte necessary for preparing a dialyzate and the pharmacologically permitted org. acids. CONSTITUTION:This dialysis pharmaceutical is formed as the laminated pharmaceutical contg. the electrolyte necessary for preparing the dialyzate contg. at least Na&lt;+&gt;, Ca&lt;++&gt;, Cl&lt;-&gt; and HCO3&lt;-&gt; and the pharmacologically permitted org. acids. Namely, the pharmaceutical is formed by laminating the inside layer contg. a core material (nucleus) and the org. acids without contg. the bicarbonate, the outside layer contg. the bicarbonate without contg. the org. acids and the intermediate layer to be interposed between the inside and outside layers. One or &gt;=2 kinds selected from a group consisting of citric acid, tartaric acid, maleic acid, oxaloacetic acid, isocitric acid and malic acid are used as the solid org. acids. As a result, the dialysis pharmaceutical which has the excellent stability and dissolves rapidly in water at the time of use is provided.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medicine for swine atrophic rhinitis comprising a recombinant dermonecrotic toxoid.  &lt;P&gt;SOLUTION: The medicine for swine atrophic rhinitis comprises as an effective ingredient a recombinant Bb-DNT (recombinant Bb-DNT toxoid) detoxified by substituting, with alanine, an amino acid in the transglutaminase active center region of a dermonecrotic toxin (Bb-DNT) produced by Bordetella bronchiseptica. The manufacturing method of the medicine is provided. A mixed vaccine comprising the recombinant Bb-DNT toxoid mixed with another vaccine for swine infectious diseases is also provided. The amino acid substitution is performed at least at one site from among the 1305-, 1320-, 1322-, and 1323-positions in SEQ ID NO.1.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT